Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 168 Cr.
- Current Price ₹ 139
- High / Low ₹ 262 / 87.0
- Stock P/E 8.83
- Book Value ₹ 100
- Dividend Yield 0.00 %
- ROCE 61.5 %
- ROE 59.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 87 | 131 | 132 | 203 | 193 | |
| 80 | 120 | 111 | 171 | 167 | |
| Operating Profit | 7 | 11 | 21 | 33 | 27 |
| OPM % | 8% | 8% | 16% | 16% | 14% |
| 0 | 0 | 1 | 2 | 1 | |
| Interest | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | 7 | 11 | 20 | 33 | 26 |
| Tax % | 25% | 27% | 27% | 26% | |
| 5 | 8 | 15 | 24 | 19 | |
| EPS in Rs | 40.38 | 56.45 | 107.00 | 25.55 | 17.76 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| TTM: | 67% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| Last Year: | 59% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 | 12 |
| Reserves | 5 | 13 | 28 | 44 | 109 |
| 6 | 11 | 13 | 17 | 1 | |
| 12 | 12 | 12 | 16 | 15 | |
| Total Liabilities | 25 | 37 | 54 | 86 | 137 |
| 1 | 6 | 5 | 9 | 9 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 24 | 32 | 48 | 77 | 128 | |
| Total Assets | 25 | 37 | 54 | 86 | 137 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -6 | 0 | -0 | 4 | |
| -1 | -5 | -0 | -4 | |
| 7 | 5 | 0 | 3 | |
| Net Cash Flow | -0 | 0 | -0 | 3 |
| Free Cash Flow | -7 | -5 | -0 | -0 |
| CFO/OP | -85% | 34% | 24% | 31% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 80 | 62 | 87 | 82 |
| Inventory Days | 9 | 25 | 27 | 50 |
| Days Payable | 41 | 34 | 33 | 23 |
| Cash Conversion Cycle | 49 | 53 | 81 | 109 |
| Working Capital Days | 28 | 25 | 66 | 75 |
| ROCE % | 58% | 63% | 62% |
Insights
In beta| Mar 2024 | Sep 2025 | |
|---|---|---|
| Blending Capacity MT/Day ・Standalone data |
|
|
| Domestic Revenue Share % ・Standalone data |
||
| Employee Strength Number ・Standalone data |
||
| Export Revenue Share % ・Standalone data |
||
| Grinding Capacity MT/Day ・Standalone data |
||
| Number of Ingredients Number ・Standalone data |
||
| Number of Trusted Clients Number ・Standalone data |
||
| Warehouse Space Sq. Ft. ・Standalone data |
||
Documents
Announcements
-
Company''s Clarification On Price Movement.
10 Apr - Chemkart clarified share price movement was market-driven, with no undisclosed material event.
-
Clarification sought from Chemkart India Ltd
10 Apr - Exchange has sought clarification from Chemkart India Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors …
-
Disclosure As Per Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015
26 Mar - Director Shailesh Mehta acquired 4,200 shares (0.03%) on 26-Mar-2026; Form C disclosure.
-
Disclosure As Per Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015
26 Mar - Ankit Mehta acquired 10,800 shares (0.09%) on 25/03/2026; disclosure filed under SEBI PIT Reg 7(2).
-
Disclosure As Per Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015
23 Mar - 23 Mar 2026: Company received Form C disclosures for designated persons' acquisition of equity shares under SEBI PIT.
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.